HGF-mediated inhibition of oxidative stress by 8-nitro-cGMP in high glucose-treated rat mesangial cells

Free Radical Research

Volumn 46, Issue 10, 2012, Pages 1238-1248

  Guoguo, Shang ^a   Akaike, Takaaki ^b   Tao, Jiang ^a   Qi, Chen ^a   Nong, Zhang ^a   Hui, Li ^a  

^a FUDAN UNIVERSITY   (China)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

8 nitro cGMP; Hepatocyte growth factor; Mesangial cells; Nrf2; Oxidative stress; Reactive oxygen species

Indexed keywords

8 NITROGUANOSINE 3'5' CYCLIC MONOPHOSPHATE; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; GLUCOSE; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; GUANYLATE CYCLASE; MALONALDEHYDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; SCATTER FACTOR; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CATALYSIS; CELL LEVEL; DIABETIC NEPHROPATHY; ENZYME SUBUNIT; MESANGIUM CELL; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; UPREGULATION;

ANIMALS; CELL NUCLEUS; CELLS, CULTURED; CYCLIC GMP; GLUCOSE; GLUTATHIONE; GUANYLATE CYCLASE; HEPATOCYTE GROWTH FACTOR; MALONDIALDEHYDE; MESANGIAL CELLS; NF-E2-RELATED FACTOR 2; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; RATS; REACTIVE OXYGEN SPECIES; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

RATTUS;

EID: 84866337195     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2012.701292     Document Type: Article

References (42)

1. Kashihara N, Haruna Y, Kondeti VK, Kanwar YS. Oxidative stress in diabetic nephropathy. Curr Med Chem 2010; 17: 4256-4269.
2. Mizuno S, Matsumoto K, Nakamura T. HGF as a renotrophic and anti-fi brotic regulator in chronic renal disease. Front Biosci 2008; 13: 7072-7086.
3. Kagawa T, Takemura G, Kosai K, Murata I, Ohno T, Takahashi T, et al. Hepatocyte growth factor gene therapy slows down the progression of diabetic nephropathy in db/db mice. Nephron Physiol 2006; 102: p92-p102. (Pubitemid 43289541)
4. Dai C, Yang J, Bastacky S, Xia J, Li Y, Liu Y. Intravenous administration of hepatocyte growth factor gene ameliorates diabetic nephropathy in mice. Am Soc Nephrol 2004; 15: 2637-2647. (Pubitemid 41103370)
5. Cruzado JM, Lloberas N, Torras J, Riera M, Fillat C, Herrero-Fresneda I, et al. Regression of advanced diabetic nephropathy by hepatocyte growth factor gene therapy in rats. Diabetes 2004; 53: 1119-1127. (Pubitemid 38436627)
6. Hui L, Hong Y, Jingjing Z, Yuan H, Qi C, Nong Z. HGF suppresses high glucose-mediated oxidative stress in mesangial cells by activation of PKG and inhibition of PKA. Free Radic Biol Med 2010; 49: 467-473.
7. Sawa T, Zaki MH, Okamoto T, Akuta T, Tokutomi Y, Kim-Mitsuyama S, et al. Protein S-guanylation by the biological signal 8-nitroguanosine 3 ′,5 ′-cyclic monophosphate. Nat Chem Biol 2007; 3: 727-735. (Pubitemid 47609113)
8. Ihara H, Ahtesham AK, Ida T, Kasamatsu S, Kunieda K, Okamoto T, Sawa T, Akaike T. Methodological proof of immunochemistry for specifi c identifi cation of 8-nitroguanosine 3 ′,5 ′-cyclic monophosphate formed in glia cells. Nitric Oxide 2011; 25: 169-175.
9. Zhang X, Cao J, Jiang L, Zhong L. Suppressive eff ects of hydroxytyrosol on oxidative stress and nuclear Factor-kappaB activation in THP-1 cells. Biol Pharm Bull 2009; 32: 578-582.
10. Fessenden JD, Coling DE, Schacht J. Detection and characterization of nitric oxide synthase in the mammalian cochlea. Brain Res 1994; 668: 9-15.
11. Fiscus RR, Murad F. cGMP-dependent protein kinase activation in intact tissues. Methods Enzymol 1988; 159: 150-159.
12. Akaike T, Fujii S, Sawa T, Ihara H. Cell signaling mediated by nitrated cyclic guanine nucleotide. Nitric Oxide 2010; 23: 166-174.
13. Ha H, Hwang IA, Park JH, Lee HB. Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. Diabetes Res Clin Pract 2008; 82(Suppl 1): S42-S45.
14. Lee SH, Nam BY, Kang EW, Han SH, Li JJ, Kim do H, et al. Eff ects of an oral adsorbent on oxidative stress and fi bronectin expression in experimental diabetic nephropathy. Nephrol Dial Transplant 2010; 25: 2134-2141.
15. Piwkowska A, Rogacka D, Jankowski M, Dominiczak MH, Stepiski JK, Angielski S. Metformin induces suppression of NAD(P)H oxidase activity in podocytes. Biochem Biophys Res Commun 2010; 393: 268-273.
16. Ebenezer PJ, Mariappan N, Elks CM, Haque M, Francis J. Diet-induced renal changes in Zucker rats are ameliorated by the superoxide dismutase mimetic TEMPOL. Obesity (Silver Spring) 2009; 17: 1994-2002.
17. Esposito C, Fasoli G, Rampino T, Dal Canton A. Hepatocyte growth factor and kidney. G Ital Nefrol 2006; 23: 381-388.
18. Hu ZX, Geng JM, Liang DM, Luo M, Li ML. Hepatocyte growth factor protects human embryonic stem cell derivedneural progenitors from hydrogen peroxide-induced apoptosis. Eur J Pharmacol 2010; 645: 23-31.
19. Valds-Arzate A, Luna A, Bucio L, Licona C, Clemens DL, Souza V, et al. Hepatocyte growth factor protects hepatocytes against oxidative injury induced by ethanol metabolism. Free Radic Biol Med 2009; 47: 424-30.
20. Zhou YJ, Yang HW, Wang XG, Zhang H. Hepatocyte growth factor prevents advanced glycation end products-induced injury and oxidative stress through a PI3K/Akt-dependent pathway in human endothelial cells. Life Sci 2009; 85: 670-677.
21. Gmez-Quiroz LE, Factor VM, Kaposi-Novak P, Coulouarn C, Conner EA, Thorgeirsson SS. Hepatocyte-specifi c c-Met deletion disrupts redox homeostasis and sensitizes to Fasmediated apoptosis. J Biol Chem 2008; 283: 14581-14589.
22. Prabhakar S, Starnes J, Shi S, Lonis B, Tran R. Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. J Am Soc Nephrol 2007; 18: 2945-2952. (Pubitemid 350058402)
23. Baylis C. Nitric oxide defi ciency in chronic kidney disease. Am J Physiol Renal Physiol 2008; 294: F1-F9.
24. Eberhardt W, Pfeilschifter J. Nitric oxide and vascular remodeling: spotlight on the kidney. Kidney Int Suppl 2007; 106: S9-S16. (Pubitemid 47172556)
25. Wani J, Carl M, Henger A, Nelson PJ, Rupprecht H. Nitric oxide modulates expression of extracellular matrix genes linked to fi brosis in kidney mesangial cells. Biol Chem 2007; 388: 497-506. (Pubitemid 46800261)
26. Prabhakar SS. Tetrahydrobiopterin reverses the inhibition of nitric oxide by high glucose in cultured murine mesangial cells. Am J Physiol Renal Physiol 2001; 281: F179-F188.
27. Xu J, Wu Y, Song P, Zhang M, Wang S, Zou MH. Proteasomedependent degradation of guanosine 5 ′-triphosphate cyclohydrolase I causes tetrahydrobiopterin defi ciency in diabetes mellitus. Circulation 2007; 116: 944-953. (Pubitemid 47300919)
28. Tousoulis D, Briasoulis A, Papageorgiou N, Tsioufi s C, Tsiamis E, Toutouzas K, Stefanadis C. Oxidative stress and endothelial function: therapeutic interventions. Recent Pat Cardiovasc Drug Discov 2011; 6: 103-114.
29. Soro-Paavonen A, Zhang WZ, Venardos K, Coughlan MT, Harris E, Tong DC, et al. Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase. J Hypertens 2010; 28: 780-788.
30. Fujii S, Sawa T, Ihara H, Tong KI, Ida T, Okamoto T, et al. The critical role of nitric oxide signaling, via protein S-guanylation and nitrated cyclic GMP, in the antioxidant adaptive response. J Biol Chem 2010; 285: 23970-23984.
31. Neo BH, Kandhi S, Ahmad M, Wolin MS. Redox regulation of guanylate cyclase and protein kinase G in vascular responses to hypoxia. Respir Physiol Neurobiol 2010; 174: 259-264.
32. Lima B, Forrester MT, Hess DT, Stamler JS. S-nitrosylation in cardiovascular signaling. Circ Res 2010; 106: 633-646.
33. Trentini P, Giordano A, Santoleri F, Di Nicola M, Bianchi G, Di Giulio C, Spoto G. cGMP phosphodiesterase activity in diabetic rats eyes in normoxic, hypoxic and hyperoxic conditions. Int J Immunopathol Pharmacol 2004; 17(3 Suppl): 17-20.
34. Radovits T, Bmicke T, Kakany G, Arif R, Loganathan S, Ks K, et al. The phosphodiesterase-5 inhibitor vardenafi l improves cardiovascular dysfunction in experimental diabetes mellitus. Br J Pharmacol 2009; 6: 909-919.
35. Baird L, Dinkova-Kostova AT. The cytoprotective role of the Keap1-Nrf2 pathway. Arch Toxicol 2011; 85: 241-272.
36. Li M, Chiu JF, Kelsen A, Lu SC, Fukagawa NK. Identifi cation and characterization of an Nrf2-mediated ARE upstream of the rat glutamate cysteine ligase catalytic subunit gene (GCLC). J Cell Biochem 2009; 107: 944-954.
37. Jiang T, Huang Z, Lin Y, Zhang Z, Fang D, Zhang DD. The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes 2010; 59: 850-860.
38. Li H, Wang F, Zhang L, Cao Y, Liu W, Hao J, Liu Q, Duan H. Modulation of Nrf2 expression alters high glucose-induced oxidative stress and antioxidant gene expression in mouse mesangial cells. Cell Signal 2011; 23: 1625-1632.
39. Cheng LL, Li B, Luo JD, Tu HB, Liu QC, Ran P. Identifi cation of an E-box motif as a transcriptional repressor element in the proximal promoter region of the GCLC gene in rat lung epithelial L2 cells. Free Radic Biol Med 2005; 39: 1030-1040. (Pubitemid 41356595)
40. Sanchez AP, Zhao J, You Y, Declves AE, Diamond-Stanic M, Sharma K. Role of the USF1 transcription factor in diabetic kidney disease. Am J Physiol Renal Physiol 2011; 301: F271-F279.
41. Visavadiya NP, Li Y, Wang S. High glucose upregulates upstream stimulatory factor 2 in human renal proximal tubular cells through angiotensin II-dependent activation of CREB. Nephron Exp Nephrol 2011; 117: e62-e70.
42. Wang S, Skorczewski J, Feng X, Mei L, Murphy-Ullrich JE. Glucose up-regulates thrombospondin 1 gene transcription and transforming growth factor-beta activity through antagonism of cGMP-dependent protein kinase repression via upstream stimulatory factor 2. J Biol Chem 2004; 279: 34311-34322. (Pubitemid 39318055)